Mentioned as a more integrated healthcare player that HIMS may struggle against if marketing efficiency drops.

Described as the 'ultimate cheapest stock' with a high Rule of 40 score and significant insider buying by the CEO.

Significant value opportunity; described as unfathomably cheap at $12 and still a major buy at $15.

Massive $12 million insider buy by the CEO indicates high conviction.

Raising prices by 30%, which may drive customers toward lower-cost competitors like HIMS.

Characterized as 'way, way, way too cheap' despite sector-wide sell-offs, representing an irrational price low.

Trading at an 'insane' low valuation while entering a bullish phase driven by 30% premium increases.

Extremely low valuation (EV/GP/RG of 0.004) with high predicted revenue growth, though viewed as a mid-term trade due to regulation.

The host is very bullish, believing the stock is significantly undervalued with 61% YoY growth guidance, a strong cash position, and trading at a 'pitiful' 0.06 times forward revenue.

Despite missing on revenue and EPS, the stock rose up to 10% due to its 'pretty damn good' forward guidance, which included 50% revenue growth in 2026.